Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy
Само за регистроване кориснике
2006
Аутори
Todorović, ZoranDžoljić, Eleonora
Novaković, Ivana
Mirković, Duško
Stojanović, Radan
Nesić, Zorica
Krajinović, Maja
Prostran, Milica

Kostić, Vladimir
Чланак у часопису (Објављена верзија)

Метаподаци
Приказ свих података о документуАпстракт
Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa treatment may give rise to elevated serum homocysteine levels in parkinsonian patients. We aimed to clarify the interplay of these factors in pathogenesis of Parkinson's disease (PD)-related hyperhomocysteinemia. Total serum levels of homocysteine (tHcy) and MTHFR C677T genotype were investigated in levodopa-treated and -untreated parkinsonian ("de novo") patients, as well as in control healthy subjects matched by age and gender (N=83, 30 and 53, respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed in app. 12-17% cases. tHcy concentrations were significantly higher in both levodopa-treated and -untreated PD patients than in control subjects, and in TT homozygotes than in CT or CC genotype carriers. tHcy levels significantly correlated with the duration of the disease in PD treated patients only, reaching the maximum after 3-6 years. H...owever, there was no correlation between tHcy levels and total daily intake of levodopa in the same group of PD patients. In conclusion, MTHFR C677T genotype is a significant factor for hyperhomocysteinemia. in patients with PD, levodopa-untreated and probably even more in levodopa-treated PD patients.
Кључне речи:
Parkinson's disease / hyperhomocysteinemia / C677T methylenetetrahydrofolate reductase polymorphism levodopaИзвор:
Journal of the Neurological Sciences, 2006, 248, 1-2, 56-61Издавач:
- Elsevier Science BV, Amsterdam
DOI: 10.1016/j.jns.2006.05.040
ISSN: 0022-510X
PubMed: 16774768
WoS: 000242305200011
Scopus: 2-s2.0-33750459018
Институција/група
PharmacyTY - JOUR AU - Todorović, Zoran AU - Džoljić, Eleonora AU - Novaković, Ivana AU - Mirković, Duško AU - Stojanović, Radan AU - Nesić, Zorica AU - Krajinović, Maja AU - Prostran, Milica AU - Kostić, Vladimir PY - 2006 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/666 AB - Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa treatment may give rise to elevated serum homocysteine levels in parkinsonian patients. We aimed to clarify the interplay of these factors in pathogenesis of Parkinson's disease (PD)-related hyperhomocysteinemia. Total serum levels of homocysteine (tHcy) and MTHFR C677T genotype were investigated in levodopa-treated and -untreated parkinsonian ("de novo") patients, as well as in control healthy subjects matched by age and gender (N=83, 30 and 53, respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed in app. 12-17% cases. tHcy concentrations were significantly higher in both levodopa-treated and -untreated PD patients than in control subjects, and in TT homozygotes than in CT or CC genotype carriers. tHcy levels significantly correlated with the duration of the disease in PD treated patients only, reaching the maximum after 3-6 years. However, there was no correlation between tHcy levels and total daily intake of levodopa in the same group of PD patients. In conclusion, MTHFR C677T genotype is a significant factor for hyperhomocysteinemia. in patients with PD, levodopa-untreated and probably even more in levodopa-treated PD patients. PB - Elsevier Science BV, Amsterdam T2 - Journal of the Neurological Sciences T1 - Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy VL - 248 IS - 1-2 SP - 56 EP - 61 DO - 10.1016/j.jns.2006.05.040 ER -
@article{ author = "Todorović, Zoran and Džoljić, Eleonora and Novaković, Ivana and Mirković, Duško and Stojanović, Radan and Nesić, Zorica and Krajinović, Maja and Prostran, Milica and Kostić, Vladimir", year = "2006", abstract = "Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa treatment may give rise to elevated serum homocysteine levels in parkinsonian patients. We aimed to clarify the interplay of these factors in pathogenesis of Parkinson's disease (PD)-related hyperhomocysteinemia. Total serum levels of homocysteine (tHcy) and MTHFR C677T genotype were investigated in levodopa-treated and -untreated parkinsonian ("de novo") patients, as well as in control healthy subjects matched by age and gender (N=83, 30 and 53, respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed in app. 12-17% cases. tHcy concentrations were significantly higher in both levodopa-treated and -untreated PD patients than in control subjects, and in TT homozygotes than in CT or CC genotype carriers. tHcy levels significantly correlated with the duration of the disease in PD treated patients only, reaching the maximum after 3-6 years. However, there was no correlation between tHcy levels and total daily intake of levodopa in the same group of PD patients. In conclusion, MTHFR C677T genotype is a significant factor for hyperhomocysteinemia. in patients with PD, levodopa-untreated and probably even more in levodopa-treated PD patients.", publisher = "Elsevier Science BV, Amsterdam", journal = "Journal of the Neurological Sciences", title = "Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy", volume = "248", number = "1-2", pages = "56-61", doi = "10.1016/j.jns.2006.05.040" }
Todorović, Z., Džoljić, E., Novaković, I., Mirković, D., Stojanović, R., Nesić, Z., Krajinović, M., Prostran, M.,& Kostić, V.. (2006). Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. in Journal of the Neurological Sciences Elsevier Science BV, Amsterdam., 248(1-2), 56-61. https://doi.org/10.1016/j.jns.2006.05.040
Todorović Z, Džoljić E, Novaković I, Mirković D, Stojanović R, Nesić Z, Krajinović M, Prostran M, Kostić V. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. in Journal of the Neurological Sciences. 2006;248(1-2):56-61. doi:10.1016/j.jns.2006.05.040 .
Todorović, Zoran, Džoljić, Eleonora, Novaković, Ivana, Mirković, Duško, Stojanović, Radan, Nesić, Zorica, Krajinović, Maja, Prostran, Milica, Kostić, Vladimir, "Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy" in Journal of the Neurological Sciences, 248, no. 1-2 (2006):56-61, https://doi.org/10.1016/j.jns.2006.05.040 . .